Table 1.
Baseline characteristics of SSc patients in GENISOS cohort *
| Characteristic | All patients (n = 447) |
Patients with available baseline neutrophil and lymphocyte counts (n=377) |
Number of patients with available data |
|---|---|---|---|
| Male gender | 77 (17.2) | 67 (17.8) | 377 |
| Age at enrollment, mean ± SD years | 48.3 ±13.3 | 48.4 ±13.3 | 377 |
| Race | 377 | ||
| White | 220 (49.2) | 187 (49.6) | |
| African American | 83 (18.6) | 69 (18.3) | |
| Latino | 124 (27.7) | 104 (27.6) | |
| Other | 20 (4.5) | 17 (4.51) | |
| Diffuse cutaneous involvement | 267 (59.9) | 223 (59.2) | 377 |
| Disease duration, mean ± SD years † | 2.5 ±1.5 | 2.47 ±1.50 | 377 |
| Anti-centromere antibody | 60 (14.1) | 46 (12.6) | 364 |
| Anti-topoisomerase I antibody | 81 (18.7) | 69 (18.6) | 372 |
| Anti-RNA polymerase III antibody | 94 (21.9) | 85 (23.0) | 369 |
| Deceased | 138 (30.9) | 122 (32.4) | 377 |
| Baseline mRSS, mean ± SD | 16.5 ±11.8 | 16.2 ±11.7 | 367 |
| Baseline FVC%, mean ± SD | 82.8 ±21.5 | 82.5 ±21.7 | 329 |
| Baseline prednisone use ∮ | 24 (6.4) | 373 | |
| Baseline immunosuppression ‡ | 97 (25.8) | 376 | |
| Methotrexate | 46 (12.2) | ||
| Mycophenolate mofetil | 32 (8.5) | ||
| Cyclophosphamide | 10 (2.7) | ||
| Azathioprine | 9 (2.4) | ||
| Other § | 7 (1.9) | ||
| Serum neutrophil count, mean ± SD # | 5,179 ±2,403 | 377 | |
| Serum lymphocyte count, mean ± SD # | 1,677 ±854 | 377 | |
| Serum neutrophil-to-lymphocyte ratio, mean ± SD | 3.93 ±3.18 | 377 |
*
GENISOS = Genetics Versus Environment In Scleroderma Outcome Study. Values are the number (percentage) unless indicated otherwise.
†
Calculated from the onset of the first non–Raynaud's phenomenon symptom
∮
Prednisone dose greater than 10 mg per day
‡
Immunosuppressants = methotrexate, mycophenolate mofetil, cyclophosphamide, and azathioprine.
§
Seven participants were on more than one immunosuppressive agent.
#
Reported as cells/μL